New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles

Alter, 1999, The prevalence of hepatitis C virus infection in the United States, 1988 through 1994, N Engl J Med, 341, 556, 10.1056/NEJM199908193410802 Fried, 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med, 347, 975, 10.1056/NEJMoa020047 CDC, 2007 Farci, 2000, The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies, Science, 288, 339, 10.1126/science.288.5464.339 Erickson, 2001, The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes, Immunity, 15, 883, 10.1016/S1074-7613(01)00245-X Ward, 2002, Cellular immune responses against hepatitis C virus: the evidence base 2002, Clin Exp Immunol, 128, 195, 10.1046/j.1365-2249.2002.01840.x Simmonds, 2005, Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, 42, 962, 10.1002/hep.20819 Logvinoff, 2004, Neutralizing antibody response during acute and chronic hepatitis C virus infection, Proc Natl Acad Sci U S A, 101, 10149, 10.1073/pnas.0403519101 Pestka, 2007, Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C, Proc Natl Acad Sci U S A, 104, 6025, 10.1073/pnas.0607026104 Dowd, 2009, Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus, Gastroenterology, 136, 2377, 10.1053/j.gastro.2009.02.080 Meunier, 2005, Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1, Proc Natl Acad Sci U S A, 102, 4560, 10.1073/pnas.0501275102 Krawczynski, 1996, Effect of immune globulin on the prevention of experimental hepatitis C virus infection, J Infect Dis, 173, 822, 10.1093/infdis/173.4.822 Yu, 2004, Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma, Proc Natl Acad Sci U S A, 101, 7705, 10.1073/pnas.0402458101 Houghton, 2005, Prospects for a vaccine against the hepatitis C virus, Nature, 436, 961, 10.1038/nature04081 Bartosch, 2003, Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes, J Exp Med, 197, 633, 10.1084/jem.20021756 Hsu, 2003, Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles, Proc Natl Acad Sci U S A, 100, 7271, 10.1073/pnas.0832180100 Wakita, 2005, Production of infectious hepatitis C virus in tissue culture from a cloned viral genome, Nat Med, 11, 791, 10.1038/nm1268 Lindenbach, 2005, Complete replication of hepatitis C virus in cell culture, Science, 309, 623, 10.1126/science.1114016 Owsianka, 2005, Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein, J Virol, 79, 11095, 10.1128/JVI.79.17.11095-11104.2005 Tarr, 2006, Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33, Hepatology, 43, 592, 10.1002/hep.21088 Law, 2008, Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge, Nat Med, 14, 25, 10.1038/nm1698 Major, 1999, Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus, J Virol, 73, 3317, 10.1128/JVI.73.4.3317-3325.1999 Puig, 2004, Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection, Vaccine, 22, 991, 10.1016/j.vaccine.2003.09.010 Dubuisson, 1994, Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses, J Virol, 68, 6147, 10.1128/JVI.68.10.6147-6160.1994 Reed, 1938, A simple method of estimating fifty per cent endpoints, Am J Hyg, 27, 493 Blight, 2002, Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication, J Virol, 76, 13001, 10.1128/JVI.76.24.13001-13014.2002 Zhang, 2009, Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity, Proc Natl Acad Sci U S A, 106, 7537, 10.1073/pnas.0902749106 Zhang, 2007, Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma, Proc Natl Acad Sci U S A, 104, 8449, 10.1073/pnas.0703039104 Major, 2004, Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees, Hepatology, 39, 1709, 10.1002/hep.20239 Johansson, 2007, Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus, Proc Natl Acad Sci U S A, 104, 16269, 10.1073/pnas.0705522104 Elmowalid, 2007, Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees, Proc Natl Acad Sci U S A, 104, 8427, 10.1073/pnas.0702162104 Li, 2008, Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses, J Virol, 82, 638, 10.1128/JVI.01691-07 Brinster, 2001, Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope, Hepatology, 34, 1206, 10.1053/jhep.2001.29304 Triyatni, 2002, Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding, Virology, 298, 124, 10.1006/viro.2002.1463 Owsianka, 2001, Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2, J Gen Virol, 82, 1877, 10.1099/0022-1317-82-8-1877 Owsianka, 2006, Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding, J Virol, 80, 8695, 10.1128/JVI.00271-06 Zibert, 1999, Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection, J Hepatol, 30, 177, 10.1016/S0168-8278(99)80059-2 Petit, 2003, Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope, J Biol Chem, 278, 44385, 10.1074/jbc.M304047200 Flint, 1999, Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81, J Virol, 73, 6235, 10.1128/JVI.73.8.6235-6244.1999 Winkler, 2000, Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody, J Immunol, 165, 4505, 10.4049/jimmunol.165.8.4505 Marchalonis, 2001, Exquisite specificity and peptide epitope recognition promiscuity, properties shared by antibodies from sharks to humans, J Mol Recognit, 14, 110, 10.1002/jmr.527 Krey, 2010, The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule, PLoS Pathog, 6, e1000762, 10.1371/journal.ppat.1000762 Davis, 2005, A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients, Liver Transpl, 11, 941, 10.1002/lt.20405